Revenue (Tables)

3 Months Ended

Mar. 28, 2025

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue

The following tables present the Company’s revenues disaggregated by geographical region and revenue type for the three-month periods ended March 28, 2025 and March 29, 2024 ($ in millions). Sales taxes and other usage-based taxes collected from customers are excluded from revenue.

	Biotechnology		Life Sciences		Diagnostics		Total
For the Three-Month Period Ended March 28, 2025:
Geographical region:
North America(a)	$	543	$	721	$	1,318	$	2,582
Western Europe	566		378		400		1,344
Other developed markets(b)	64		123		91		278
High-growth markets(c)	439		458		640		1,537
Total	$	1,612	$	1,680	$	2,449	$	5,741
Revenue type:
Recurring	$	1,457	$	1,136	$	2,223	$	4,816
Nonrecurring	155		544		226		925
Total	$	1,612	$	1,680	$	2,449	$	5,741
For the Three-Month Period Ended March 29, 2024:
Geographical region:
North America(a)	$	514	$	781	$	1,337	$	2,632
Western Europe	546		372		406		1,324
Other developed markets(b)	79		125		99		303
High-growth markets(c)	385		467		685		1,537
Total	$	1,524	$	1,745	$	2,527	$	5,796
Revenue type:
Recurring	$	1,309	$	1,192	$	2,294	$	4,795
Nonrecurring	215		553		233		1,001
Total	$	1,524	$	1,745	$	2,527	$	5,796

(a) The Company defines North America as the United States and Canada.

(b) The Company defines other developed markets as all the markets of the world that are not North America, Western Europe or high-growth markets.

(c) The Company defines high-growth markets as developing markets of the world experiencing accelerated growth, over extended periods, in gross domestic product and infrastructure which include Eastern Europe, the Middle East, Africa, Latin America (including Mexico) and Asia (with the exception of Japan, Australia and New Zealand). The Company defines developed markets as all markets of the world that are not high-growth markets.